Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
ASTHMA: OTHER THERAPIES

OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA

Wanda Phipatanakul
Pediatrics August 2003, 112 (Supplement 2) 486;
Wanda Phipatanakul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF

Buhl R, Soler M, Matz J, et al. Eur Respir J. 2002;20:73–78

Purpose of the Study.

To examine the ability of omalizumab, an anti-immunoglobulin E (anti-IgE) agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma.

Study Population.

Four hundred eighty-three patients with moderate-to-severe allergic asthma maintained on beclomethasone diproprionate.

Methods.

Four hundred eighty-three patients with physician-diagnosed moderate-to-severe allergic asthma were investigated in a 24-week double-blind extension trial. These patients were a subset of 546 patients that were maintained on randomized treatment of omalizumab during a 28-week double blind steroid reduction phase of the core trial. During the 28-week steroid reduction phase of the core trial, the lowest sustainable dose of beclomethasone diproprionate was established. Patients in this trial had positive prick skin tests to common inhalant allergens and IgE levels of >30 to <700 IU/mL. The extension part of the trial was a 24-week double blind extension with placebo control. Standard doses of omalizaub were used throughout the 24-week extension period and given every 2 to 4 weeks based on body weight and IgE level. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the beclomethasone diproprionate dose or switch patients from beclomethasone diproprionate to other asthma medications if deemed necessary. Patients were followed clinically for asthma symptoms and exacerbations. Mean doses of inhaled corticosteroids and other asthma medications were recorded, and forced expiratory volume in 1 second (FEV1) by spirometry was recorded.

Results.

More omalizumab-treated patients (33.5%) than placebo-treated patients (13.5%) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean beclomethasone diproprionate equivalent dose throughout the extension period was lower in the omalizumab group (25 μg/day) than the placebo group (43 μg/day). Disease control was sustained in 76% of omalizumab patients compared with 59.4% of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medications during the extension. Treatment with omalizumab was well-tolerated and the incidence of adverse events was similar between groups.

Conclusions.

These results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma.

Reviewer’s Comments.

The role of anti-IgE therapy in asthma and other allergic diseases is a topic of increasing interest as these drugs may soon come to market. This study nicely shows that omalizumab provides long-term benefit and hints of a possible steroid-sparing effect, which is always of increasing interest with the widespread use of inhaled corticosteroids. However, additional long-term studies are needed to better assess the overall cost benefit analysis of these products. They are likely to be very expensive and if only a minimal steroid-sparing effect is found, their role may be very limited.

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 112, Issue Supplement 2
1 Aug 2003
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA
Wanda Phipatanakul
Pediatrics Aug 2003, 112 (Supplement 2) 486;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA
Wanda Phipatanakul
Pediatrics Aug 2003, 112 (Supplement 2) 486;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Purpose of the Study.
    • Study Population.
    • Methods.
    • Results.
    • Conclusions.
    • Reviewer’s Comments.
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

ASTHMA: OTHER THERAPIES

  • THE ROLE OF ANTICHOLINERGICS IN ACUTE ASTHMA TREATMENT
  • SELECTIVE INTRACELLULAR DELIVERY OF DEXAMETHASONE INTO ACTIVATED ENDOTHELIAL CELLS USING AN E-SELECTIN-DIRECTED IMMUNOCONJUGATE
Show more ASTHMA: OTHER THERAPIES

ABSTRACTS

  • THE ROLE OF ANTICHOLINERGICS IN ACUTE ASTHMA TREATMENT
  • SELECTIVE INTRACELLULAR DELIVERY OF DEXAMETHASONE INTO ACTIVATED ENDOTHELIAL CELLS USING AN E-SELECTIN-DIRECTED IMMUNOCONJUGATE
  • ANTIBODY DEFICIENCY AND AUTOIMMUNITY IN 22q11.2 DELETION SYNDROME
Show more ABSTRACTS

Similar Articles

Subjects

  • Allergy/Immunology
    • Allergy/Immunology
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics